Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Slides:



Advertisements
Similar presentations
Palumbo A et al. Proc ASH 2012;Abstract 446.
Advertisements

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
The Nurse’s Role in Inflammatory Bowel Disease
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
How I treat extramedullary myeloma
Diabetic Dyslipidemia in Practice
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma
Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.
Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
Improving Survival in Glioblastoma Multiforme
Challenging Cases in Multiple Myeloma Panel Discussion
Post-autologous Transplant Therapy for Hodgkin Lymphoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Updates in Hodgkin Lymphoma
Modifying Disease Course in Alzheimer's Disease
Progression After Cancer Immunotherapy in Advanced NSCLC
What Predicts Disability Progression in Multiple Sclerosis?
Selecting Therapy for Relapsed/ Refractory Multiple Myeloma
Optimizing Outcomes in the Management of GIST
Current and Future Goals in the Treatment of Relapsed CLL
Clinical Cases in Glaucoma Treatment
Treating Transplant-Ineligible Patients With Multiple Myeloma
Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.
Goals of Therapy in Relapsed CLL
Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.
Challenges in Managing Progressive Multiple Sclerosis
IL-17 Inhibitors in the Management of Psoriatic Disease
The Nurse View: Best Practices in Multiple Myeloma
Disease Activity Assessment Across the RA Continuum
Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.
Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Evaluating Next-Generation BTK Inhibitors
Illustrations in Ulcerative Colitis
Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.
Treating to Target in MS
Introduction. Clinical Scenario: Encouraging Adherence in Patients with Schizophrenia.
Approaches in Newly Diagnosed Multiple Myeloma: When and What
Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.
Staying Abreast of Best Practices Across the Clinical Continuum
Program Goals Overview Is NEDA a Reasonable Target?
Maintenance Therapy in Advanced Ovarian Cancer
The Road to Quality Improvement in HER2-Positive Breast Cancer
Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
The Role of Maintenance Therapy in Multiple Myeloma
Are We Making Progress in the Management of Huntington Disease?
Proteasome Inhibitors and Patients
Communicating With Your Patients About Major Depressive Disorder
On the Cusp: New Approaches for Multiple Myeloma
Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators
Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.
From Adjuvant to Metastatic in Melanoma
The Role of Measurable Residual Disease in AML
Renal Function and Myeloma Therapeutics
Program Goals Overview Is NEDA a Reasonable Target?
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
Spotlight on Monoclonal Antibodies in Multiple Myeloma
A Closer Look.
Minimal Residual Disease and Hematologic Malignancies
Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.
What's New in Rare CKDs?.
Navigating the Journey
Fresh perspectives ON BASAL Insulins in diabetes care
Presentation transcript:

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Multiple Myeloma How to decide what to do at first relapse?

Early Relapsed Multiple Myeloma Carfilzomib and Pomalidomide

Relapsed Multiple Myeloma Try to use therapies for as long as they work.

Early Relapsed Multiple Myeloma Duration of Therapy

Duration of Therapy Try to treat for at least 8 cycles or to best response and not until progression.

Duration of Therapy Patients with short second remission or high-risk disease should be treated continuously until progression.

Early Relapsed Multiple Myeloma Role and Timing of 2nd HDT/ASCT

2nd HDT/ASCT at Relapse Use for patients who had at least 3-year remission after first HDT/ASCT, and follow by alternative maintenance therapy to what they had previously.

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)